Medical Condition News

RSS

RAD to restore SCI's Radiation Treatment Center

Swedish Cancer Institute (SCI) has embarked on a bold approach to rapidly restore community-based radiotherapy cancer treatment in the Ballard community utilizing state-of-the-art building technology that is swift and green.

16 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

Miracor Medical Systems GmbH announced today that the company has received CE-mark for the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, designed to improve acute coronary syndrome (ACS) revascularization following primary percutaneous coronary intervention (PCI).

16 Dec 2010

Oxygen Biotherapeutics and SMP sign Binding Letter of Intent for joint chronic ischemic wound research

Oxygen Biotherapeutics, Inc. and privately held Sarasota Medical Products, Inc. (SMP) of Sarasota, FL, today announced they signed a Binding Letter of Intent to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds. The venture will be based on combining Oxygen's Wundecyte™ PFC formulation with SMP's topical medical devices.

16 Dec 2010

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.

16 Dec 2010

Study finds that immobilization devices significantly reduce braking response time

Patients recovering from a right foot injury or surgery should think twice about how soon they want to begin driving again. According to a new study from the Journal of Bone and Joint Surgery (JBJS), it takes much longer to brake when the driver is wearing an immobilization device - like a splint or brace, than it does when wearing normal footwear.

16 Dec 2010

MDA commits to invest funds in FSMA Quinazoline Program

The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA.

16 Dec 2010

Alzheimer's Foundation of America praises House, Senate passage of National Alzheimer's Project Act

The Alzheimer's Foundation of America issued this statement today regarding passage of the National Alzheimer's Project Act. The National Alzheimer's Project Act would create the National Alzheimer's Project, which would coordinate government efforts to prevent and treat the disease and create a national strategy for defeating Alzheimer's disease.

16 Dec 2010

Study describes CC3/TIP30 protein regulate metabolic adaptation of tumor cells to glucose limitation

Bionovo, today announced the publication of a study entitled "CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation" in the journal Cell Cycle.

16 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Envoy's successfull application of bacTRAP technology triggers milestone payment from Merck

Envoy Therapeutics, a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck.

16 Dec 2010

Three million Western Europeans suffer from critical limb ischemia

A recent analysis published by THE SAGE GROUP concluded that 3 million people in Western Europe have critical limb ischemia (CLI). Reflecting the aging population, this number is projected to grow to 4 million by 2030.

16 Dec 2010

Study reports protective shield fluoride on teeth is 100 times thinner

In a study that the authors describe as lending credence to the idiom, "by the skin of your teeth," scientists are reporting that the protective shield fluoride forms on teeth is up to 100 times thinner than previously believed.

16 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both "Clusters of excellence", Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects are dedicated to the development of new biological products based on the Lauriad™ technology allowing mucous penetration of a biologically active compound.

16 Dec 2010

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.

16 Dec 2010

New study records show dementia residents seek hospice benefit

A new study of nursing home records shows more residents with dementia are seeking a hospice benefit and using it longer. The study also estimates that 40 percent of nursing home residents die with some degree of dementia.

16 Dec 2010

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen, or PSA.

16 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

16 Dec 2010

Medical Condition News

RAD to restore SCI's Radiation Treatment Center

Adeona expands and enhances zinc-based product candidate portfolio

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

Oxygen Biotherapeutics and SMP sign Binding Letter of Intent for joint chronic ischemic wound research

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Study finds that immobilization devices significantly reduce braking response time

MDA commits to invest funds in FSMA Quinazoline Program

Alzheimer's Foundation of America praises House, Senate passage of National Alzheimer's Project Act

Study describes CC3/TIP30 protein regulate metabolic adaptation of tumor cells to glucose limitation

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Envoy's successfull application of bacTRAP technology triggers milestone payment from Merck

Three million Western Europeans suffer from critical limb ischemia

Study reports protective shield fluoride on teeth is 100 times thinner

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

New study records show dementia residents seek hospice benefit

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News